Repare Therapeutics Inc.
RPTX evidence brief
What we can confirm
- BioSniper Score:
- 6.6 / 10
- Market Cap:
- $114.2M
- Lead Asset:
- Camonsertib (RP-3500) (Phase 2)
What it means
What to watch
Prepared research question
What matters most for RPTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Tracking 4 pipeline candidates · 9 clinical trials for Repare Therapeutics Inc..
Run Repare Therapeutics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Repare Therapeutics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 2
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Governance
Frequently asked questions
What is Repare Therapeutics Inc.'s lead drug candidate?
Repare Therapeutics Inc.'s most advanced tracked candidate is Camonsertib (RP-3500) (Phase 2) for Solid Tumor; Chronic Lymphocytic Leukemia; Advanced Cancer.
Who is the CEO of Repare Therapeutics Inc.?
Mr. Steve Forte CPA is the chief executive officer of Repare Therapeutics Inc. (RPTX).
Where is Repare Therapeutics Inc. headquartered?
Repare Therapeutics Inc. (RPTX) is headquartered in Montreal, QC, Canada.
What therapeutic areas does Repare Therapeutics Inc. focus on?
Repare Therapeutics Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.